Tevogen Bio Announces $8 Million Equity Investment
February 15, 2024 09:25 AM Eastern Standard Time WARREN, N.J.–(BUSINESS WIRE)–On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics…